Olivier RABIN – Montréal

Olivier Rabin

Biographie 

Senior Director, Science and Medicine WADA (World Anti-Doping Agency) Montréal, Canada

 

Effective July 2021, Prof. Olivier Rabin assumed the role of Senior Director, Science and Medicine. In this capacity, Prof. Rabin oversees the List of Prohibited Substances and Methods (Prohibited List), the Athlete Biological Passport (ABP), the areas of scientific research, medical, and anti-doping laboratories, while also establishing international partnerships in the fields of science and medicine. 

Olivier joined WADA as Science Director in 2002 and was later named Executive Director, Science and International Partnerships. 

Over the years, Olivier has established an international reputation as an expert in pharmaceutical research and development. Prior to joining WADA, he worked for over seven years for IPSEN Pharma, in the United Kingdom and in France, in the fields of research and business development. In this capacity, he was responsible for international development of new medicines and led scientific and medical teams for in-depth assessment of various international projects in the pharmaceutical sector.

Prior to his work at IPSEN, Olivier was a principal investigator of research in pharmacology and toxicology for government organizations, including having spent four years at the National Institutes of Health in the United States, where he was responsible for a cerebral ischemia program and development of pharmacological strategies for brain neuroprotection. He also worked at the Institut National de la Santé et de la Recherche Médicale in Paris (France).

Over the course of his career, Olivier has been instrumental in establishing partnerships with high profile public or private organizations.

Olivier has a PhD in fundamental and applied toxicology and a degree in biomedical engineering. He is the author of numerous scientific publications and books in anti-doping and emerging drugs in sports. He was appointed Distinguished Visiting Professor at the University of Trento (Italy) in April 2023.